426 related articles for article (PubMed ID: 3275486)
1. The Intergroup Rhabdomyosarcoma Study-I. A final report.
Maurer HM; Beltangady M; Gehan EA; Crist W; Hammond D; Hays DM; Heyn R; Lawrence W; Newton W; Ortega J
Cancer; 1988 Jan; 61(2):209-20. PubMed ID: 3275486
[TBL] [Abstract][Full Text] [Related]
2. The Intergroup Rhabdomyosarcoma Study-II.
Maurer HM; Gehan EA; Beltangady M; Crist W; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J
Cancer; 1993 Mar; 71(5):1904-22. PubMed ID: 8448756
[TBL] [Abstract][Full Text] [Related]
3. The Third Intergroup Rhabdomyosarcoma Study.
Crist W; Gehan EA; Ragab AH; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J; Heyn R
J Clin Oncol; 1995 Mar; 13(3):610-30. PubMed ID: 7884423
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
[TBL] [Abstract][Full Text] [Related]
6. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (clinical groups III and IV). The Intergroup Rhabdomyosarcoma Study (IRS) Committee of the Cancer and Leukemia Group B Children's Cancer Study Group, Southwest Oncology Group.
Raney RB; Gehan EA; Maurer HM; Newton WA; Ragab AH; Ruymann FB; Sutow WW; Tefft M
Cancer Clin Trials; 1979; 2(1):19-28. PubMed ID: 391431
[TBL] [Abstract][Full Text] [Related]
8. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
[TBL] [Abstract][Full Text] [Related]
9. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
10. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center.
Ortega JA; Donaldson SS; Ivy SP; Pappo A; Maurer HM
Cancer; 1997 Jun; 79(12):2435-9. PubMed ID: 9191535
[TBL] [Abstract][Full Text] [Related]
11. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan AA; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
J Clin Oncol; 2014 Nov; 32(31):3547-52. PubMed ID: 25267746
[TBL] [Abstract][Full Text] [Related]
12. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608
[TBL] [Abstract][Full Text] [Related]
13. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
Koscielniak E; Jürgens H; Winkler K; Bürger D; Herbst M; Keim M; Bernhard G; Treuner J
Cancer; 1992 Nov; 70(10):2557-67. PubMed ID: 1482503
[TBL] [Abstract][Full Text] [Related]
14. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
[TBL] [Abstract][Full Text] [Related]
15. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
16. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
[TBL] [Abstract][Full Text] [Related]
17. Results of intensive therapy in children with localized alveolar extremity rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study.
Heyn R; Beltangady M; Hays D; Lawrence W; Newton W; Crist W; Tefft M; Maurer HM
J Clin Oncol; 1989 Feb; 7(2):200-7. PubMed ID: 2915235
[TBL] [Abstract][Full Text] [Related]
18. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
Baker KS; Anderson JR; Link MP; Grier HE; Qualman SJ; Maurer HM; Breneman JC; Wiener ES; Crist WM
J Clin Oncol; 2000 Jun; 18(12):2427-34. PubMed ID: 10856103
[TBL] [Abstract][Full Text] [Related]
19. Bladder and prostatic tumors in the intergroup Rhabdomyosarcoma study (IRS-I): results of therapy.
Hays DM; Raney RB; Lawrence W; Soule EH; Gehan EA; Tefft M
Cancer; 1982 Oct; 50(8):1472-82. PubMed ID: 6749275
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study.
Ruymann FB; Newton WA; Ragab AH; Donaldson MH; Foulkes M
Cancer; 1984 Jan; 53(2):368-73. PubMed ID: 6546301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
